PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY

被引：0
|
作者：
Mendell, J. [1 ]
Gewitz, A. [1 ]
Wang, Y. [1 ]
Harnisch, L. [1 ]
Olenchock, B. [1 ]
Pan, H. [1 ]
Podgrabinska, S. [1 ]
Zheng, W. [1 ]
Zhao, A. [1 ]
Vanhoutte, F. [2 ]
Davis, J. [1 ]
机构：
[1] Regeneron Pharmaceut, Tarrytown, NY USA
[2] SGS Clin Pharmacol Unit, Antwerp, Belgium
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-074
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [41] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
    Christopher John Wynne
    Alexandra Cole
    Charlotte Lemech
    Guoqin Wang
    Yu Zhang
    Benchao Chen
    Max Wang
    Baiyong Li
    Michelle Xia
    Rodney Sinclair
    Dermatology and Therapy, 2023, 13 : 2357 - 2373
  • [42] FIRST-IN-HUMAN PHASE 1 STUDY OF EA3571, WHICH IS A NOVEL DUAL INHIBITOR OF ENTEROPEPTIDASE AND TRYPSIN WITH LUMINAL ACTION, IN HEALTHY ADULT PARTICIPANTS
    Umeda, Atsushi
    Owada, Yasuko
    Furihata, Kenichi
    Tsuruoka, Shuichi
    Nakajima, Atsushi
    Mikami, Ryosuke
    Oaku, Masakaze
    Yamamoto, Takuya
    Yano, Tetsuo
    Kumagai, Yuji
    HEPATOLOGY, 2024, 80 : S433 - S434
  • [43] Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
    Playford, Elliott Geoffrey
    Munro, Trent
    Mahler, Stephen M.
    Elliott, Suzanne
    Gerometta, Michael
    Hoger, Kym L.
    Jones, Martina L.
    Griffin, Paul
    Lynch, Kathleen D.
    Carroll, Heidi
    El Saadi, Debra
    Gilmour, Margaret E.
    Hughes, Benjamin
    Hughes, Karen
    Huang, Edwin
    de Bakker, Christopher
    Klein, Reuben
    Scher, Mark G.
    Smith, Ina L.
    Wang, Lin-Fa
    Lambert, Stephen B.
    Dimitrov, Dimiter S.
    Gray, Peter P.
    Broder, Christopher C.
    LANCET INFECTIOUS DISEASES, 2020, 20 (04): : 445 - 454
  • [44] Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study
    Prokopienko, Alexander J.
    Wang, Junyao
    Yajnik, Vijay
    Baratta, Mike
    Desai, Nirav K.
    Richmond, Camilla A.
    Suri, Ajit
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (02): : 217 - 225
  • [45] Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials
    Kosloski, Matthew P.
    Kalliolias, George D.
    Xu, Christine R.
    Harel, Sivan
    Lai, Ching-Ha
    Zheng, Wenjun
    Davis, John D.
    Kamal, Mohamed A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 384 - 395
  • [46] First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers
    Rein-Hedin, Erik
    Sjoberg, Folke
    Waters, Susanna
    Sonesson, Clas
    Waters, Nicholas
    Huss, Fredrik
    Tedroff, Joakim
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (12): : 1485 - 1494
  • [47] Tolerability and kinetics of SYNB1020 in a Phase 1, first-in-Human, healthy adult volunteer study
    Puurunen, M.
    Denney, W. S.
    Blankstein, L.
    Goldwater, R.
    Parsons, T.
    Millet, Y.
    Kurtz, C.
    Brennan, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S737 - S737
  • [48] Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
    Richard, Frank
    van Lier, Jan Jaap
    Roubert, Bernard
    Haboubi, Teba
    Gohring, Udo-Michael
    Durrenberger, Franz
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (01) : 68 - 77
  • [49] ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study
    Heymach, J
    West, H
    Kerr, R
    Prager, D
    Sandler, A
    Herbst, R
    Stewart, D
    Dimery, I
    Johnson, B
    LUNG CANCER, 2005, 49 : S247 - S248
  • [50] Ghrelin agonist (TZP-101): Safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: A phase I, first-in-human study
    Lasseter, Kenneth C.
    Shaughnessy, Laura
    Cummings, David
    Pezzullo, John C.
    Wargin, William
    Gagnon, Rene
    Oliva, Jesus
    Kosutic, Gordana
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (02): : 193 - 202
12345